⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22944867 | 0.83 | — | — | |
| SCHEMBL1723957 | 0.79 | ADORA2A (0.43) | — | |
| SCHEMBL2826206 | 0.77 | ADORA2B (0.44) | — | |
| SCHEMBL31330327 | 0.74 | ADORA2A (0.33) | — | |
| SCHEMBL31330241 | 0.74 | ADORA2A (0.33) | — | |
| SCHEMBL31330313 | 0.74 | ADORA2A (0.33) | — | |
| SCHEMBL31330324 | 0.71 | ADORA2A (0.33) | — | |
| SCHEMBL31330242 | 0.70 | ADORA2A (0.31) | — | |
| SCHEMBL22562822 | 0.68 | CYP1A2 (0.34) | — | |
| SCHEMBL8463363 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368092-A1 | 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-11-07 | — | — | US | claimed |
| WO-2024249959-A1 | COMPOSITIONS REDUCING THE EXPRESSION OR ACTIVITY OF C1 GALT1 FOR TREATING EWING SARCOMA | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240368092-A1 | 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-11-07 | — | — | US | disclosed |
| US-20220395503-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| EP-4100124-A1 | HETEROCYCLIC COMPOUNDS AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20210087529-A1 | CBL INHIBITORS AND COMPOSITIONS FOR USE IN ADOPTIVE CELL THERAPY | NURIX THERAPEUTICS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20200323904-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | NURIX THERAPEUTICS, INC. | 2020-10-15 | — | — | US | disclosed |
| US-9981956-B2 | Small molecule inhibitors of fibrosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170217943-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-08-03 | — | — | US | disclosed |
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | disclosed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| EP-2611785-A1 | N-(TETRAZOL-5-YL)- AND N-(TRIAZOL-5-YL)ARYLCARBOXAMIDES AND USE THEREOF AS HERBICIDES | Bayer Intellectual Property GmbH (DE) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028579-A1 | N-(TETRAZOL-5-YL)- AND N-(TRIAZOL-5-YL)ARYLCARBOXAMIDES AND USE THEREOF AS HERBICIDES | BAYER CROPSCIENCE AG (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-0283992-A2 | 4-[4-[4-[4-[[2-(2,4-Difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]-methoxy]phenyl]-1-piperazinyl]phenyl]triazolones | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-09-28 | — | — | EP | disclosed |